

August 05, 2024

National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex (BKC) Bandra (east) Mumbai - 400051	BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400001
Symbol: EQUITASBNK	Scrip Code No:543243

Dear Sir

Sub: Newspaper Advertisement on Eighth Annual General Meeting (AGM) of the Bank

Please find enclosed herewith the copies of advertisements published in Business Standard and Makkal Kural (in all editions) on August 05, 2024, inter-alia notifying the Eighth AGM of the Bank scheduled on September 10, 2024 and procedure for registration/update of e-mail addresses.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

For **Equitas Small Finance Bank Limited**

N Ramanathan
Company Secretary

Encl: a/a



BEYOND BANKING

When you bank with us, you contribute towards a better society.

Equitas Small Finance Bank Limited
(Previously known as Equitas Finance Limited)

4th Floor, Phase II, Spencer Plaza, No.769, Mount Road, Anna Salai, Chennai, Tamil Nadu, India - 600 002

T: +91 44 4299 5000 | F: +91 44 4299 5050 | corporate@equitas.in | www.equitasbank.com | Toll Free: 1800 103 1222 | CIN No: L65191TN1993PLC025280

EQUITAS SMALL FINANCE BANK LIMITED
Regd. Office: 4th Floor, Phase II, Spencer Plaza, 769, Mount Road, Anna Salai, Chennai-600002. Ph: + 91 44 4299 5000 Email: cs@equitasbank.com

Notice for the Attention of Shareholders of the Bank
EIGHTH ANNUAL GENERAL MEETING OF EQUITAS SMALL FINANCE BANK LIMITED AND INFORMATION ON RECEIVING NOTICE & ANNUAL REPORT

The Eighth Annual General Meeting (AGM) of the Bank will be held on Tuesday, September 10, 2024 at 11.00 A.M. I.S.T. through Video Conferencing (VC) / Other Audio Visual Means (OAVM) in compliance with all the applicable provisions of the Companies Act, 2013 and the Rules made thereunder, the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/4 dated January 05, 2023, read with the General Circulars Nos. 20/2020, 20/2021, 02/2022, 10/2022 dated 5 May 2020, 14 December 2021, 5 May 2022 and 28 December 2022 issued by the Ministry of Corporate Affairs ("MCA") (hereinafter collectively referred to as "the Circulars") for holding of AGM through VC / OAVM, to transact the businesses as set out in the Notice of Eighth AGM.

In compliance with the above circulars, the electronic copies of Notice of the Eighth AGM along with the Annual report of 2023-24 will be sent only to the registered e-mail addresses of the shareholders available with the Bank / Depository Participant(s) and will also be made available on the websites of the Bank https://ir.equitasbank.com/, the stock exchanges viz., BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com. The requirement to send physical copies of the Notice of the AGM along with the Annual report of FY 2023-2024 to shareholders holding physical shares and those who have not registered their email addresses has been dispensed with for the ensuing Annual General Meeting in accordance with the aforesaid SEBI and MCA Circulars.

Manner of registering / updating email addresses is as below:
1. Members who have not registered their email addresses and mobile numbers till date are requested to register the same in respect of shares held in dematerialised mode with their relevant Depositories through their Depository Participants
2. Physical shareholders are hereby notified that based on SEBI Circular / Master Circular no. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/37 dated March 16, 2023 and SEBI/HO/MIRSD/PoD-1/P/CIR/2024/37 dated May 07, 2024, all holders of physical shares in listed companies shall register the postal address with PIN for their corresponding folio numbers. It shall be mandatory for the security holders to provide mobile number. Moreover, to avail online services, the security holders can register their e-mail ID. Shareholder can register / update the contact details through submitting the requisite ISR 1 form along with the supporting documents.

ISR 1 Form can be downloaded by visiting the link: https://karisma.kfintech.com/downloads/2Form_ISR-1.pdf
3. ISR Form(s) and the supporting documents are to be forwarded to RTA by sending hard copies which are self-attested, to the following address: KFIN Technologies Limited, Selenium Building, Tower-B, Plot No 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy, Telangana - 500 032. Detailed FAQ can be found on the link: https://ris.kfintech.com/faq.html

For more information on updating the email and Mobile details for securities held in electronic mode, please reach out to the respective DP(s), where the DEMAT a/c is held.

4. After verification, the Bank/RTA will forward the Annual report for FY 2023-24 along with the Notice of 8th AGM to the registered email addresses.

5. The Bank will be providing remote e-voting facility to all its Members to cast their vote on the businesses as set forth in the Notice of the Eighth AGM. Additionally, during the AGM, the Bank will be providing the facility of e-voting through e-voting system. The elaborate instructions of the process of e-voting including the procedure for participation of Members holding shares in physical form and Members who have not registered their email addresses, through remote e-voting or e-voting system during the AGM will be provided as part of the Notice of the Eighth AGM.

6. Shareholders may note that the Board of Directors in their meeting held on April 24, 2024, has recommended a dividend of Re. 1/- per equity share. The record date for the purpose of dividend for the financial year ended March 31, 2024 is August 9, 2024. The dividend, once approved by the shareholders in the ensuing AGM will be paid electronically within the statutory timelines through online transfer modes to those shareholders who have updated their bank account details. For shareholders who have not updated their bank account details, dividend warrants/ demand drafts/ cheques will be sent to their registered address. To avoid delay in receiving dividend, shareholders are requested to update their KYC with their depositories (where shares are held in dematerialized mode) and with the Bank's RTA (where shares are held in physical mode) to receive dividend directly into their bank account on the payout date.

7. Shareholders whose shareholding is in dematerialized mode are requested to notify any change in address or bank account details to their respective Depository Participant(s). Shareholders whose shareholding is in physical mode are requested to opt for the Electronic Clearing System (ECS) mode to receive dividend on time in line with the Circulars. Members are requested to note the following contact details for addressing queries / grievances, if any:

Company Secretary, Equitas Small Finance Bank Limited, 4th Floor, Phase-II, Spencer Plaza, 769, Mount Road, Anna Salai, Chennai - 600 002. Phone: +91 44 42995000; Fax: +9144 42995050, Email: cs@equitasbank.com
KFIN Technologies Limited, Selenium Tower B, Plot No 31-32, Gachibowli Financial District Nanakramguda, Hyderabad-500032 Toll Free Number- 1800-309-4001 Email : einward.ris@kfintech.com
For Equitas Small Finance Bank Limited Sd/- Ramanathan N, Company Secretary

THE ASKA COOPERATIVE SUGAR INDUSTRIES LTD.
P.O. Nuagam (Aska) - 761111, Ganjam District, Odisha
email: askasugar@yahoo.co.in, GSTIN : 21AAAT5989L1Z0

SHORT QUOTATION CALL NOTICE

Letter No.(Engg.)/864 Dt.01.08.2024
The Aska Co-operative Sugar Industries Ltd.Aska invites sealed quotation from reputed consultant/Firms for preparation of details project reports (DPR) in respect setting up 30TPH Bagasse fired boiler and 2.5MW power plant in the premises of Aska Co-operative Sugar Industries Ltd., Nugam, Dist-Ganjam, Odisha-761111. Interested consultant/Firms are requested to give their offer for above mentioned job on or before dt.14.08.2024 at 05:00P.M. Please visit our website www.askasugar.com for detailed Short Quotation Call Notice. Managing Director

Chemcon Speciality Chemicals Limited
(An ISO 9001:2015 and ISO 14001:2015 Certified Company)
Regd. Office : Block Number 355, Manjusr Kumpad Road, Manjusr Village, Taluka Savli, Vadodara 391775, Gujarat.
Email : investor.relations@cschl.com | Website : www.cschl.com | Tel : +91 265 298 1195 | CIN : L2423GJ1988PL011652

EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2024

Table with 4 columns: Particulars, Quarter Ended (30-06-2024, 31-03-2024, 30-06-2023, 31-03-2024) and (Rs. in Lacs). Rows include Total income from operations, Net Profit/Loss, Total Comprehensive Income, Equity Share Capital, etc.

Notes:
1. The above is an extract of the detailed format of Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Company's website at www.cschl.com and the Stock Exchange's Website at www.bseindia.com and www.nseindia.com.

By order of the Board
For Chemcon Speciality Chemicals Limited
Sd/- Kamalkumar Rajendra Aggarwal
Chairman & Managing Director
DIN: 00139199
Place : Vadodara
Date : 3rd August, 2024

NSE NATIONAL STOCK EXCHANGE OF INDIA LTD.
Exchange Plaza, C-1, Block G, Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051, Maharashtra, India.
Public Notice
Public Notice for Compulsory Delisting of Equity Shares of Companies in terms of Regulation 32 (5) (a) of SEBI (Delisting of Equity Shares) Regulations, 2021

Table with 4 columns: Name and Registered office address of the Company, Fair value (Rs. per share), Name of the Promoters of the Company, Address of the Promoters of the company. Rows include Soni Soya Products Limited and Javed Ali.

* Address available as per the records of the MCA/Exchange.
** Address available as per the records of the Exchange.

Notes:
The consequences of compulsory delisting include the following:
a. In terms of Regulation 34(1) of the Delisting Regulations, the Company, its whole-time directors, person(s) responsible for ensuring compliance with the securities laws, its promoters and the companies which are promoted by any of them shall not directly or indirectly access the securities market or seek listing of any equity shares or act as an intermediary in the securities market for a period of ten (10) years from the date of such delisting.

b. In case of a company whose fair value is positive-
i. such a company and the depositories shall not effect transfer, by way of sale, pledge, etc., of any of the equity shares held by the promoters / promoter group and the corporate benefits like dividend, rights, bonus shares, split, etc. shall be frozen for all the equity shares held by the promoters/ promoter group, till the promoters of such company provide an exit option to the public shareholders in compliance with sub-regulation (4) of regulation 33 of these regulations, as certified by the relevant recognized stock exchange;
ii. the promoters, whole-time directors and person(s) responsible for ensuring compliance with the securities laws, of the compulsorily delisted company shall also not be eligible to become directors of any listed company till the exit option as mentioned in clause (a) is provided.

c. The onset of giving exit to the public shareholders is on the promoters of the company.
d. In terms of Regulation 33(4) of Delisting Regulations, the promoter(s) of the company shall acquire the delisted equity shares from the public shareholders by paying them the value determined by the valuer, within three months of the date of delisting from the recognised stock exchange, subject to the option of the public shareholders to retain their shares.

e. In terms of Regulation 33(5) of Delisting Regulations, the promoter shall be liable to pay interest at the rate of ten percent per annum to all the shareholders, who offer their shares under the compulsory delisting offer, if the price payable in terms of sub-regulation (3) of Regulation 33 is not paid to all the shareholders within the time specified under sub-regulation (4).
Any queries can be addressed to The Delisting Committee, Listing Department, National Stock Exchange of India Limited 'Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex, Bandra (East), Mumbai 400 051. Contact no: +91 22 26598400 (3014). E-mail: vgandhi@nse.co.in, delisting@nse.co.in with cc to dt-insp-enf-delisting@nse.co.in.

The queries should be mandatorily emailed to the above specified email address. Any anonymous queries would not be considered valid
Place: Mumbai
Date: August 05, 2024
For and on behalf of National Stock Exchange of India Limited

ARAGEN LIFE SCIENCES LIMITED
(formerly known as Aragen Life Sciences Private Limited)
CIN: U74999TG2000PLC035826
Registered and Corporate Office: Plot 28A, IDA Nacharam, Hyderabad, Telangana-500076, India
Tel: +91 40 6692 9999 F: +91 40 6692 9900
Email id: compliances@aragen.com, website: www.aragen.com

Extract of standalone financial results for the quarter ended 30 June 2024 (amount in ₹ million)

Table with 5 columns: S. No., Particulars, 30 June 2024 Unaudited, 31 March 2024 Audited (Refer Note 6), 30 June 2023 Unaudited, 31 March 2024 Audited. Rows include Total Income from operations, Net Profit, Total Comprehensive Income, Equity Share Capital, etc.

Notes:
1. The above is an extract of the detailed format of quarterly/annual financial results filed with the Stock Exchange(s) under regulation 52 of the Listing Regulations. The above financial results have been reviewed and recommended by the Audit Committee at its meeting held on 29 July 2024 and approved by the Board of Directors at its meeting held on 02 August 2024. These Financial Results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act 2013 read with the relevant rules there under and the other accounting principles generally accepted in India.

2. For the other line items referred in Regulation 52(4) of the LODR Regulations, pertinent disclosures have been made to the stock exchange, BSE Limited, and can be accessed at www.bseindia.com. The full format of the quarterly/annual financial results including detailed notes thereon are available on the websites of the stock exchange- BSE Limited at www.bseindia.com and the Company at www.aragen.com.
3. During the year ended 31 March 2022, the Company had issued 2,000 rated, listed, redeemable, Non-convertible Debentures (NCDs) of face value ₹ 1,000,000 each for a total amount of ₹ 2,000 million on a private placement basis. These NCDs have been listed on the Stock Exchange (BSE Limited) with effect from 14 February 2022. The NCDs are repayable at the end of 36 months from the date of allotment and carry an annual interest rate of 7.75% per annum due on 11 February of every year.

4. In terms of regulation 54(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the NCDs are secured by first charge on Property, plant & equipment, movable CWIP including immovable property at Mallapur unit with minimum asset cover of 1.25x.
5. During the quarter ended 30 June 2024, the Company had not received any complaints from the NCD holders and there has been no complaint pending for redressal at the beginning or at the end of the quarter. The equity shares of the Company are not listed on any Stock Exchange.

6. Figures for the quarter ended 31 March 2024 represents the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figures up to the third quarter of the respective financial years.
7. The statutory auditors of the Company ("B S R and Co") have carried out a limited review of the above unaudited standalone financial results for the quarter ended 30 June 2024 and have issued an unmodified review report. The review report of the Statutory auditors was filed with the BSE Limited and also is available on the Company's website.

8. Subsequent to Quarter ended 30 June 2024, the Company has transferred its 100% stake in Aragen Bioscience, Inc., to its wholly owned subsidiary, i.e., Aragen Biologics Private Limited on 02 July 2024.

For Aragen Life Sciences Limited
Sd/- Manmahesh Kantipudi
Whole-time Director & CEO
Date : 02 August 2024
Place : Hyderabad
DIN:05241166

JKTYRE & INDUSTRIES LTD.
Net Profit 33%
CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2024
Table with 4 columns: SL No., PARTICULARS, 30.06.2024 Unaudited, 30.06.2023 Unaudited, 31.03.2024 Audited. Rows include Revenue from Operations, Operating Profit, Net Profit, etc.
Notes:
* Standalone financial information of the Company, pursuant to regulation 47(1)(b):
Table with 4 columns: PARTICULARS, 30.06.2024 Unaudited, 30.06.2023 Unaudited, 31.03.2024 Audited. Rows include Turnover, Operating Profit, Profit before Tax, Profit after Tax.
Standalone Financial Results for the Quarter ended 30.06.2024 can be viewed on websites of the Company, National Stock Exchange of India Ltd. and BSE Ltd. at www.jktyre.com, www.nseindia.com and www.bseindia.com respectively.
* The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites (URL- www.bseindia.com and www.nseindia.com) and on website of the Company at www.jktyre.com.
JK Tyre adjudged 'Best in Class' ESG rating from CareEdge for the second consecutive year
For JK Tyre & Industries Limited
Udaipur 3rd August, 2024
Raghupati Singhania
Chairman & Managing Director
Admin. Office: 3, Bahadur Shah Zafar Marg, New Delhi-110 002, Fax: 91-11-23322059, Phone: 91-11-66001112, 66001122
Regd. Office: Jaykaygram, PO – Tyre Factory, Kankroli – 313 342, Rajasthan, Website: www.jktyre.com
Corporate Identity Number: L67120RJ1951PLC045966

